Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2010 / Cilt: 44 - Sayı: 1

Investigation of serum visfatin levels in patients with psoriasis

Psoriasisli hastalarda serum visfatin düzeylerinin araştırılması

Pages
15–18
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These results demonstrated that visfatin may not play a significant role in the immunopathogenesis of psoriasis but visfatin could be accepted as a nonspecific inflammatory marker to correlated severity of the disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: Psoriasis is a chronic, recurrent, T-cell mediated inflammatory skin disease with multifactorial etiology.
📊
Key Findings & Data:It was shown that visfatin, an adipocytokine, induces expression of the tumor necrosis factor-a (TNF-a), interleukin (IL)-1b, IL-6 ve IL-8 in previous studies.
💡
Conclusion & Impact:Conclusion: These results demonstrated that visfatin may not play a significant role in the immunopathogenesis of psoriasis but visfatin could be accepted as a nonspecific inflammatory marker to correlated severity of the disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background and Design: Psoriasis is a chronic, recurrent, T-cell mediated inflammatory skin disease with multifactorial etiology. It was shown that visfatin, an adipocytokine, induces expression of the tumor necrosis factor-a (TNF-a), interleukin (IL)-1b, IL-6 ve IL-8 in previous studies. In the present study, we aimed to investigate serum visfatin levels and relation between visfatin and psoriasis severity. Material and Method: Forty psoriatic patient and 40 healthy controls were included in this study. Serum visfatin, IL-6, TNF-a and CRP levels were measured in all participant and PASI scores of the psoriatic patients were estimated. Results: The mean serum visfatin and IL-6 levels were not statistically different in psoriatic patients compared with controls (p=0.509 and p=0.213). Serum TNF-a levels were significantly higher in patients with psoriasis than in healthy controls (p=0.015). There was no statistically significant difference in CRP levels between two groups (p=0.370). However, there was positive correlation between PASI scores and serum visfatin or CRP levels respectively (p=0.001, p=0.002). The positive correlation was also found between serum visfatin and CRP levels (p=0.029). Conclusion: These results demonstrated that visfatin may not play a significant role in the immunopathogenesis of psoriasis but visfatin could be accepted as a nonspecific inflammatory marker to correlated severity of the disease.

Özet

Amaç: Psoriasis multifaktöriyel etyolojili, kronik, tekrarlayıcı, T hücre aracılı nflamatuvar bir deri hastalığıdır. Bir adipositokin olan visfatinin, tümör nekrozis faktör-a (TNF-a), interlökin (IL)-1b, IL-6 ve IL-8 gibi inflamatuvar sitokinlerin ekspresyonunu indüklediğini gösteren çok sayıda çalışma mevcuttur.Bu çalışmada psoriasiste serum visfatin düzeyleri ve bunun hastalık şiddeti ilişkisinin araştırılması amaçlanmıştır. Gereç ve Yöntem: Çalışmaya 40 psoriasisli hasta ve 40 sağlıklı kontrol dahil edildi. Hasta ve kontrol grubunda serum visfatin, TNF-a, IL-6 ve C reaktif protein (CRP) düzeyleri ölçüldü. Ayrıca hasta grubunun Psoriasis Area Severity Index (PASI) skorları belirlendi. Bulgular: Hasta ve kontrol gruplarında serum visfatin ve IL-6 düzeyleri arasındaki fark istatistiksel olarak anlamlı değildi (p=0,509 ve p=0,213). Hasta grubundaki serum TNF-a düzeyleri kontrol grubuna kıyasla istatistiksel olarak anlamlı şekilde yüksek bulundu. (p=0,015). CRP değerleri açısından iki grup arasında istatistiksel olarak anlamlı fark yoktu (p=0,370). Ancak PASI ile visfatin ve CRP değerleri arasında güçlü düzeyde pozitif yönde korelasyon saptandı (p=0,001, p=0,002). Ayrıca serum visfatin düzeyleri ile CRP arasında da orta düzeyde pozitif yönde korelasyon bulundu (p=0,029). Sonuç: Sonuçlar visfatinin psoriasis patogenezinde önemli bir rolünün olmadığını ancak hastalık şiddetiyle ilişkili nonspesifik bir inflamatuvar belirteç olabileceğini göstermektedir.

🔖

Cite This Article

YILDIRIM, M., BOZKURT, N. M., CEYHAN, A. M., VURAL, H., KARA, Y. (2022). Investigation of serum visfatin levels in patients with psoriasis. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 44 - Sayı: 1, 15–18. https://ajindex.com/articles/622012

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Erdal E: Psoriasis etyopatogenezi. T Klin J Dermatol 2004;14:11-4
  2. Yazıcı AC, Karabulut AA: Psoriazisin genetik özellikleri ve patogenezi. Dermatose 2003;2:95-102
  3. Luk T, Malam Z, Marshall JC: Pre-B cell colony enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008;83:804-16
  4. Moschen AR, Kaser A, Enrich B et al: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58
  5. Tilg H, Moschen AR: Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008;114:275-88
  6. Pilz S, Mangge H, Obermayer-Pietsch B, März W: Visfatin/pre-Bcell colony-enhancing factor: a protein with various suggested functions. J Endocrinol Invest 2007;30:138-44
  7. Hug C, Lodish HF: Visfatin: a new adipokine. Science 2005;307:366-7
  8. Oki K, Yamane K, Kamei N, Nojima H, Kohno N: Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol 2007;67:796-800
  9. Kendal CE, Bryant-Greenwood GD: Pre-B-cell colony-enhancing factor (PBEF/Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells. Placenta 2007;28:305-14
  10. Otero M, Lago R, Gomez R et al: Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198-201
  11. Brentano F, Schorr O, Ospelt C et al: Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007;56:2829-39
  12. Koczan D, Guthke R, Thiesen HJ et al: Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005;15:251-7
  13. Bilen N: Non-püstüler psoriyazis. T Klin J Int Med Sci 2005;1:22-6
  14. Özden MG, Tekin NS: Psoriazis patogenezinde yenilikler. T Klin J Dermatol 2007;17:112-9
  15. Zhou X, Krueger JG, Kao MCJ et al: Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003;13:69-78
  16. Ergün A: Ya¤ dokusu ve ya¤ hücresi. T Klin J Med Sci 2005;25:412-20
  17. Takematsu H, Tagami H: Lack of correlation between interleukin 6 and interleukin 1 levels in psoriatic lesional skin. Tohoku J Exp Med 1994;172:243-52